- Login
- Register & Subscribe
- Language: EN FR DE
Finance, Grants, Deals
Targovax funds pancreatic cancer vaccine
Thursday 2 February 2012
A Norwegian start-up company,Targovax AS, has raised NOK 13 million (€1.7 million) in a Series A financing round to support the clinical development of a therapeutic vaccine against pancreatic cancer. The candidate product is a peptide vaccine that targets mutations on ras genes.
Location
Norway
Wilex successfully completes rights offering
Wednesday 1 February 2012
Wilex AG, which has an antibody treatment for renal cell cancer in a pivotal Stage 3 trial along with a companion diagnostic, has successfully completed a €9.93 million rights issue. Wilex is based in Munich, Germany.
Location
Germany
Domain Therapeutics receives grant for PD
Tuesday 31 January 2012
Venture-capital backed Domain Therapeutics SA of France has received a grant from the Michael J. Fox Foundation to develop allosteric modulators for Parkinson’s disease. This follows a year-earlier licensing deal with Merck Serono, also for PD.
Location
France
Amgen to buy Micromet for $1.16 billion
Thursday 26 January 2012
Amgen Inc has agreed to pay $1.16 billion in cash to acquire Micromet Inc, a developer of bispecific antibodies. Micromet’s key asset is blinatumomab, an antibody in early clinical development against acute lymphoblastic leukaemia.
Location
United States
Celgene to acquire Avila Therapeutics
Thursday 26 January 2012
Celgene Corp said it has reached agreement to acquire venture-capital backed Avila Therapeutics Inc for $350 million in cash, plus milestones, thereby strengthening its position in the area of haematologic cancers.
Location
United States
CN Creative raises £2 million in Series A
Thursday 26 January 2012
A UK start-up, CN Creative Ltd, which has developed an electronic smoking cessation device, has raised £2 million in a Series A round led by Advent Life Sciences. The money will support final development of its novel inhaler product.
Location
United Kingdom
Roche makes hostile bid for Illumina
Wednesday 25 January 2012
The Roche group has stepped up its commitment to personalised medicine with the announcement of a hostile $5.7 billion bid for Illumina Inc of the US, a leading provider of molecular diagnostics. The all-cash offer values each share at $44.50.
Location
Switzerland
Prosensa raises €23 million for RNA-based drugs
Wednesday 25 January 2012
Privately-owned Prosensa Therapeutics BV of the Netherlands has raised €23 million to support its pipeline which includes a Phase 3 RNA-modulating therapeutic for Duchenne muscular dystrophy. New Enterprise Associates Inc led the financing.
Location
Netherlands
Clavis Pharma reports delay in AML trial
Wednesday 18 January 2012
Clavis Pharma ASA has announced a delay in the start of a Phase 3 study of its new treatment for acute myeloid leukaemia (AML). Separately, the Norwegian oncology company said it has raised NOK 163 in a private share placement with investors.
Location
Norway
Evotec expands alliance with Harvard University
Tuesday 17 January 2012
Evotec AG has announced a second strategic alliance with Harvard University, this time to discover and develop biomarkers and treatments for kidney disease. This follows an earlier deal to develop diabetes therapies targeting beta cell regeneration.
Location
Germany
Select a News Category
Recent Appointments
Carolyn Compton named CEO of Critical Path Institute
Friday February 3 2012
John Perkins appointed UK chief scientific advisor
Monday January 23 2012
Briggs Morrison to lead global medicines development at AstraZeneca
Wednesday January 11 2012
Russell Greig appointed chair of AM-Pharma supervisory board
Wednesday January 4 2012
Mark Bodmer to head immunology at UCB
Tuesday January 3 2012